These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 15889780

  • 1. Framing the threat of resistance to quinolones in pharmacologic terms.
    Ambrose PG.
    Manag Care Interface; 2005 Apr; Suppl():4-6. PubMed ID: 15889780
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predicting the future Streptococcus pneumoniae resistance landscape.
    Mera R.
    Curr Opin Pharmacol; 2005 Oct; 5(5):459-64. PubMed ID: 16084768
    [Abstract] [Full Text] [Related]

  • 6. Olamufloxacin. Hokuriku Seiyaku.
    Jiraskova N.
    Curr Opin Investig Drugs; 2000 Sep; 1(1):31-4. PubMed ID: 11249592
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Where are quinolones going? New agents in development].
    Holzgrabe U.
    Pharm Unserer Zeit; 2001 Sep; 30(5):446-8. PubMed ID: 11575182
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones.
    Fenoll A, Giménez MJ, Robledo O, Coronel P, Gimeno M, Casal J, Aguilar L.
    Int J Antimicrob Agents; 2007 Feb; 29(2):224-6. PubMed ID: 17175141
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Quinolones for brucellosis: treating old diseases with new drugs.
    Pappas G, Christou L, Akritidis N, Tsianos EV.
    Clin Microbiol Infect; 2006 Sep; 12(9):823-5. PubMed ID: 16882286
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Streptococcus pneumoniae resistance to quinolones and its relationship with the use of antibiotics].
    Solís del Baño S.
    Rev Esp Quimioter; 2005 Mar; 18(1):86-9. PubMed ID: 15915242
    [No Abstract] [Full Text] [Related]

  • 16. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?
    Fenoll A, Aguilar L, Granizo JJ, Giménez MJ, Aragoneses-Fenoll L, Mendez C, Tarragó D.
    J Antimicrob Chemother; 2008 Dec; 62(6):1430-3. PubMed ID: 18819966
    [Abstract] [Full Text] [Related]

  • 17. Analysis of dual active fluoroquinolones in Streptococcus pneumoniae.
    Fisher LM, Gould KA, Pan XS, Patel S, Heaton VJ.
    J Antimicrob Chemother; 2003 Aug; 52(2):312-3; author reply 313-4. PubMed ID: 12865396
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations.
    Avrain L, Garvey M, Mesaros N, Glupczynski Y, Mingeot-Leclercq MP, Piddock LJ, Tulkens PM, Vanhoof R, Van Bambeke F.
    J Antimicrob Chemother; 2007 Nov; 60(5):965-72. PubMed ID: 17693451
    [Abstract] [Full Text] [Related]

  • 20. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ, Schurek KN, Decorby MR, Weshnoweski B, Vashisht R, Karlowsky K, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.